Autopsy report · NCT00522548
Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
Cause of deathOther
“enrollment halted in order to have all patients complete follow-up by Jan 2011”
Life of this trial
- Registered 5 months after it had already started.
- Ran for about 3 years 10 months before it stopped.
- 37 participants enrolled.
- Results were posted on the registry 7 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Conditions
- Transplants and Implants
- Interventions
- Enteric coated mycophenolate sodium; Mycophenolate mofetil
- Participants
- 37
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement
“Enrollment of patients has halted prematurely and will not resume. No future patients will be enrolled or treated.” - Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility
“No further patient enrollment” - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
“Enrollment halted prematurely due to the Covid-19 pandemic” - Growth Hormone Therapy for Wasting in Cystic Fibrosis
“Poor enrollment, patients were lost to follow up” - Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
“closed to enrollment due to slow patient accrual”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.